Filtered By:
Infectious Disease: Hepatitis C
Drug: Norvir

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 157 results found since Jan 2013.

New hepatitis C drug treatment 'shows promise'
Conclusion Although designed as an RCT, the study had an analysis of drug effectiveness that becomes more like a single cohort of people receiving an active treatment, with no comparison arm. People were assigned to the five-drug combination or matching placebos for 12 weeks. During this time, the side effects in both treatment groups were monitored and these could be compared, with itching and anaemia occurring more commonly in the active treatment group. However, the double-blind drug treatment period was completed at 12 weeks and response outcomes were then assessed 12 weeks later. Twelve weeks later, the active treatm...
Source: NHS News Feed - April 14, 2014 Category: Consumer Health News Tags: Medication Medical practice Source Type: news

Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience
Conclusions PrOD plus ribavirin had a highly satisfactory real-world efficacy and safety profile in the treatment of recurrent HCV-1 infection after liver transplantation in Asian patients.
Source: Journal of the Formosan Medical Association - June 27, 2017 Category: General Medicine Source Type: research

The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents
Publication date: Available online 5 August 2017 Source:The Kaohsiung Journal of Medical Sciences Author(s): Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Meng-Hsuan Hsieh, Jeng-Fu Yang, Ching-I. Huang, Yi-Hung Lin, Po-Cheng Liang, Zu-Yau Lin, Shinn-Chern Chen, Ming-Lung Yu, Wan-Long Chuang Direct-acting antiviral agents (DAAs) have been widely used for chronic hepatitis C (CHC) treatment recently. The characteristics of glucose abnormalities after DAAs therapy however, remain elusive. We aimed to elucidate the mutual impact between treatment response and parameters of glucose abnormalities after DAAs therap...
Source: The Kaohsiung Journal of Medical Sciences - August 6, 2017 Category: Universities & Medical Training Source Type: research

Change in hepatic profile in hepatitis C virus genotype 4 patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: a subanalysis of the AGATE ‐II study
Journal of Medical Virology,Volume 0, Issue ja, -Not available-.
Source: Journal of Medical Virology - June 14, 2018 Category: Virology Authors: ImamWaked , GamalEsmat , RababFouad , NaglaaAllam , MohamedHassany , MohammadMohey , GamalShiha , RehamSoliman , Roula BQaqish , ColeenHall , Negar NAlami , SarahKopecky ‐Bromberg , NiloufarMobashery Source Type: research

Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience
ConclusionPrOD plus ribavirin had a highly satisfactory real-world efficacy and safety profile in the treatment of recurrent HCV-1 infection after liver transplantation in Asian patients.
Source: Journal of the Formosan Medical Association - July 5, 2018 Category: General Medicine Source Type: research

Change in the hepatic profile of hepatitis C virus genotype 4 –infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE‐II study
Journal of Medical Virology, EarlyView.
Source: Journal of Medical Virology - July 16, 2018 Category: Virology Authors: ImamWaked MD , GamalEsmat , RababFouad , NaglaaAllam , MohamedHassany , MohammadMohey , GamalShiha , RehamSoliman , Roula B.Qaqish , ColeenHall , Negar N.Alami , SarahKopecky ‐Bromberg , NiloufarMobashery Source Type: research

Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis
ConclusionsThis real-word experience study confirmed similar, high effectiveness of 8 and 12-weeks regimens of OPrD in genotype 1b HCV infected patients with non-advanced fibrosis. Despite of reduced SVR rate after 8-weeks regimen, there is no need to extend therapy to 12-weeks in vast majority of such patients and no need to add ribavirin.
Source: Advances in Medical Sciences - December 13, 2019 Category: Biomedical Science Source Type: research

A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania
CONCLUSIONS Ombitasvir, paritaprevir, and ritonavir combined with dasabuvir, with or without ribavirin had an efficacy rate of over 99% in HCV genotype 1b infection. We report no serious adverse reactions.PMID:35787600 | DOI:10.12659/MSM.936706
Source: Medical Science Monitor - July 5, 2022 Category: Research Authors: Xenia Bacinschi Gabriel Cristian Popescu Anca Zgura Laurentia Gales Anghel Rodica Adriana Mercan Dragos Serban Bogdan Haineala Letitia Toma Laura Iliescu Source Type: research

Review article: safety and tolerability of direct‐acting anti‐viral agents in the new era of hepatitis C therapy
ConclusionsWith the impending reality of a more tolerable interferon‐sparing regimen, the future of DAA therapy offers shorter treatment duration, simplified disease management, and a patient‐centred regimen. With advantages come drawbacks, including development of resistance to therapy and accessibility to this expensive treatment. DAA therapy continues to advance at a brisk pace with a promising trend for higher tolerability, even in difficult‐to‐treat subgroups such as those with cirrhosis, nonresponders to prior therapy, and transplant recipients. Subgroup‐specific contraindications and safety‐related limit...
Source: Alimentary Pharmacology and Therapeutics - January 21, 2016 Category: Drugs & Pharmacology Authors: D. Banerjee, K. R. Reddy Tags: Review Article Source Type: research

Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment.
This article summarizes a presentation by Lucas Hill, PharmD, at the IAS-USA continuing education program held in Chicago, Illinois, in October 2014. PMID: 26200709 [PubMed - in process]
Source: Topics in antiviral medicine - July 25, 2015 Category: Infectious Diseases Tags: Top Antivir Med Source Type: research

A Special Touch: Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection.
CONCLUSION: Depending on the population studied, clinicians must consider differences in efficacy outcomes, potential drug interactions, and adverse effects that patients may experience. PMID: 26139639 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - July 2, 2015 Category: Drugs & Pharmacology Authors: Toussaint-Miller KA, Andres J Tags: Ann Pharmacother Source Type: research

Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study
Conclusions In treatment-naive/-experienced HCV-1/HIV-1 patients there were significantly higher SVR rates with telaprevir-based therapy compared with pre-specified historical controls, and safety comparable to that in HCV-monoinfected patients.
Source: Journal of Antimicrobial Chemotherapy - December 16, 2015 Category: Microbiology Authors: Montes, M. L., Nelson, M., Girard, P.-M., Sasadeusz, J., Horban, A., Grinsztejn, B., Zakharova, N., Rivero, A., Durant, J., Ortega-Gonzalez, E., Lathouwers, E., Janssen, K., Ouwerkerk-Mahadevan, S., Witek, J., Gonzalez-Garcia, J. Tags: Original research Source Type: research

Efficacy and safety of direct ‐acting antivirals‐based antiviral therapies for hepatitis C virus patients with stage 4‐5 chronic kidney disease: a meta‐analysis
ConclusionsDAA‐based antiviral therapies are effective and well‐tolerated for HCV patients with stage 4‐5 chronic kidney disease.
Source: Liver International - January 1, 2017 Category: Gastroenterology Authors: Tao Li, Yundong Qu, Ying Guo, Yan Wang, Lei Wang Tags: ORIGINAL ARTICLE Source Type: research